Shigehiro Yanagita

Shigehiro Yanagita

Auto-generated profile, based on publicly available information

Shigehiro Yanagita

Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
KOK. Okubo
K. Okubo
YUY. Uenosono
Y. Uenosono
TATakaaki Arigami
Takaaki Arigami
YMY. Mataki
Y. Mataki
Daisuke MatsushitaDaisuke Matsushita
Daisuke Matsushita
SNS. Natsugoe
S. Natsugoe

1 April 2008 in Journal of Surgical Research
Verified
Journal Article
Closed access
SYShigehiro Yanagita
Shigehiro Yanagita
SNShoji Natsugoe
Shoji Natsugoe
YUYoshikazu Uenosono
Yoshikazu Uenosono
TKTsutomu Kozono
Tsutomu Kozono
KEKatsuhiko Ehi
Katsuhiko Ehi
TATakashi Aikou
Takashi Aikou

30 September 2008 in Surgical Oncology
Verified
Journal Article
Closed access
SYShigehiro Yanagita
Shigehiro Yanagita
SNShoji Natsugoe
Shoji Natsugoe
YUYoshikazu Uenosono
Yoshikazu Uenosono
TATakaaki Arigami
Takaaki Arigami
HAHideo Arima
Hideo Arima
TATakashi Aikou
Takashi Aikou

24 April 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
MSMasataka Shimonosono
Masataka Shimonosono
TATakaaki Arigami
Takaaki Arigami
SYShigehiro Yanagita
Shigehiro Yanagita
DMDaisuke Matsushita
Daisuke Matsushita
YUYasuto Uchikado
Yasuto Uchikado
SNShoji Natsugoe
Shoji Natsugoe
The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) expression with gastric cancer prognosis The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) expression with gastric cancer prognosis

19 December 2007 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SYShigehiro Yanagita
Shigehiro Yanagita
SNShoji Natsugoe
Shoji Natsugoe
YUYoshikazu Uenosono
Yoshikazu Uenosono
HAHideo Arima
Hideo Arima
TKTsutomu Kozono
Tsutomu Kozono
TATakashi Aikou
Takashi Aikou

1 September 2009 in Oncology
Verified
Journal Article
Closed access
SYShigehiro Yanagita
Shigehiro Yanagita
SNShoji Natsugoe
Shoji Natsugoe
YUYoshikazu Uenosono
Yoshikazu Uenosono
TATakaaki Arigami
Takaaki Arigami
YFYawara Funasako
Yawara Funasako
TATakashi Aikou
Takashi Aikou
Background: Lymph node metastasis is the most important prognostic factor in gastric cancer. However, diagnosis by hematoxylin and eosin staining or immunohistochemistry is not always sufficient for the detection of cancer cells because only representative number of slices are examined. Cancer cells may, therefore, be missed by traditional histological methods. Recently, reverse transcription polymerase chain reaction (RT-PCR) methods have been introduced for improved detection of cancer cells. The purpose of this study was to evaluate the utility of a prototype RT-PCR assay run on the Cepheid SmartCycler® system compared to conventional RT-PCR using the LightCycler® system. Patients and Methods: Forty-seven overt metastatic lymph nodes from 8 patients with advanced gastric cancer and 22 benign lymph nodes from patients without malignant tumor who received surgery were obtained with informed consent. We examined the lymph nodes by RT-PCR, using markers for CEA and CK19 and the LightCycler and SmartCycler systems. Results: In the singlex assay, the sensitivity of CEA and CK19 was 91.5 and 70.2% in the LightCycler system, and 97.9 and 95.7% in the SmartCycler system, respectively. In the multiplex assay, the sensitivity was 91.5% in the LightCycler system and 100% in the SmartCycler system, respectively. Conclusion: In this study, rapid diagnosis using RT-PCR by the SmartCycler system had higher accuracy for detecting lymph node metastasis than the conventional LightCycler system. The SmartCycler system is more effective for the diagnosis of lymph node metastasis in gastric cancer when run with the prototype assay.